Suggested remit: To appraise the clinical and cost effectiveness of pegvaliase within its marketing authorisation for treating phenylketonuria.
Please note this appraisal has now been discontinued.
 
Status Discontinued
Technology type Medicine
Decision Selected
Process STA Standard
ID number 1110

Email enquiries

Timeline

Key events during the development of the guidance:

Date Update
08 January 2024 Discontinued. Please note this appraisal has now been discontinued.
29 November 2018 The Department for Health and Social Care has asked NICE to carry out an appraisal of pegvaliase within its marketing authorisation for treating phenylketonuria. Following on from advice received from the company the timelines for this appraisal are to be confirmed, whilst the company await the outcome of an ongoing European trial (OPTIC Study). The evidence from this study is critical to provide the necessary health economic evidence that will strongly support the NICE appraisal. Further information regarding the scheduling of this appraisal will be provided in due course.
27 June 2018 (10:00) Scoping workshop (London)
10 May 2018 - 08 June 2018 Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators

For further information on our processes and methods, please see our CHTE processes and methods manual